



December 6, 2023

Name of listed company: AIN HOLDINGS INC.  
Exchange listed on: Tokyo Prime Market, Sapporo Securities Exchange  
Code number: 9627  
Representative: Kiichi Otani, President and Representative Director  
Inquiries: Toshihide Mizushima, Representative Senior Managing Director  
TEL: +81-11-814-1000

Notice on the Differences Between Consolidated Financial Forecasts and Results for the First Six Months of the Fiscal Year and Revisions to Full-Year Consolidated Financial Forecasts

We would like to announce that there were differences between consolidated financial forecasts, announced on June 2, 2023, and results for the first six months of the fiscal year ending April 30, 2024, announced today. Based on the results, revisions have been made to full-year consolidated financial forecasts for the fiscal year ending April 30, 2024.

1. Differences between consolidated financial forecasts and results for the first six months of the fiscal year ending April 30, 2024 (May 1, 2023 to October 31, 2023)

(Million yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share (Yen)
Previous Forecast (A)	183,459	6,087	6,421	3,185	90.66
Result (B)	193,727	8,749	9,338	5,257	149.66
Difference (B-A)	10,268	2,662	2,917	2,072	
Rate of Difference (%)	5.6	43.7	45.4	65.1	
(Ref.) Results for the First Six Months of the Fiscal Year Ended April 30, 2023	171,204	6,786	7,285	3,805	108.32

Note: In the third quarter of the fiscal year ended April 30, 2023, the Company finalized provisional accounting treatment related to a business combination. Results for the first quarter of the fiscal year ending April 30, 2023 reflect the finalized figures.

2. Revisions to full-year consolidated financial forecasts for the fiscal year ending April 30, 2024.  
(May 1, 2023 to April 30, 2024)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share (Yen)
Previous Forecast (A)	375,000	15,663	16,302	8,250	234.84
Latest Forecast (B)	390,263	18,450	19,340	10,000	284.64
Change (B-A)	15,263	2,787	3,038	1,750	
Rate of Change (%)	4.1	17.8	18.6	21.2	
(Ref.) Results for the First Six Months of the Year Ended April 30, 2023	358,742	16,004	17,064	9,234	262.87

3. Reasons for the differences and the revisions

During the first six months of the current fiscal year (May 1, 2023 to October 31, 2023), the consolidated financial results exceeded the previously announced forecasts for the reasons below. In the dispensing pharmacy business, in addition to the number of prescriptions increased, the average prescription price rose due to an increase in high-cost prescriptions, including COVID-19 treatments. In the cosmetic and drug store business, customer numbers were firm amid a recovery. Also, the average sales price increased, and costs reduced due to the customer buying habits changed from infection control products to cosmetics.

In light of the above, the Company has revised its full-year consolidated financial forecasts for the fiscal year ending April 30, 2024, released on June 2, 2023.

The revisions have not resulted in any change to the Company's dividend forecast.

Please refer to today's release "Summary of Financial Statements for the Second Quarter of Fiscal Year Ending April 2024" released today for the results for the first six months of the fiscal year ending April 30, 2024.

Note: The above business performance forecasts have been produced based on information presently available.

It is possible that in the future actual results may differ from the anticipated figures for a variety of reasons.